An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00207155

Enrollment

110

Registered

2005-09-21

Start date

2003-12-31

Completion date

2006-02-28

Last updated

2015-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Colorectal Cancer

Brief summary

The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer

Interventions

DRUGCetuximab

IV solution, IV, 400 mg/m2 initial dose + 250-400 mg/m2 weekly, Weekly, Until disease progression.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Measurable disease Tumor available for biopsies. Life expectancy of at least 3 months.

Exclusion criteria

* Known or documented brain metastases prior to Cetuximab therapy.

Design outcomes

Primary

Measure	Time frame
Prediction of response to Erbitux in subjects with metastatic colorectal cancer	—

Secondary

Measure	Time frame
Radiographic Response	—

Countries

Canada, Spain, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026